Q3 FY23 Earnings Presentation slide image

Q3 FY23 Earnings Presentation

Cardiovascular 7% growth driven by strong performance in CRM, TAVR, & Diagnostics Cardiac Rhythm & Heart Failure (CRHF) • • • Cardiac Pacing Therapies: HSD growth; mid-teens WW Micra™ growth driven by China Micra TM AV launch and increased market penetration Defibrillation Solutions: HSD growth driven by strong implant rates and ICD replacement headwinds subsiding; Aurora EV-ICDTM1 CE Mark received last week Procedure Innovations: Low-20s growth on strength of TYRXTM antibacterial envelopes CAS: HSD WW ex. China growth driven by continued adoption of Arctic Front™ cryoablation catheters, offset by competitive pressure in Europe and China VBP; PulseSelect™ PFA catheter¹ PULSED AF pivotal trial results to be presented as a LBCT at ACC.23 on March 6th Diagnostics: LINQ IITM global launch expansion accelerates with unrestricted supply Structural Heart & Aortic (SHA) Structural Heart: LDD WW & U.S. TAVR growth driven by EvolutTM FX launch and SVD Durability Data showing CoreValve TM and Evolut™ as first and only TAVR platforms to outperform SAVR at 5 years Aortic: DD growth on supply improvements for both AAA & TAA; continued pressure from Valiant Navion TM recall Coronary and Peripheral Vascular (CPV) Coronary: Y/Y & sequential DES share gains driven by Onyx Frontier™ launch; U.S. & WE PCI procedures below pre-COVID levels Peripheral Vascular Health: Growth in DCBs, Vascular Embolization, and Superficial Venous offset by weakness in Directional Atherectomy, Peripheral Stents and PTA balloons 10 Q3 FY23 Earnings Presentation | February 21, 2023 Micra TM AV and VR Transcatheter Pacing System Medtronic Micra AV Arctic Front™ cryoablation catheters LINQ II™M Insertable Cardiac Monitor Evolut™ FX TAVR System 21% CPV | $581M -3.6% Y/Y Rep +1.5% Y/Y Org $2,772M +1.0% Y/Y Rep +6.5% Y/Y Org 27% SHA $760M +2.7% Y/Y Rep +8.8% Y/Y Org ......52% CRHF $1,431M +2.1% Y/Y Rep +7.5% Y/Y Org Operating Unit Growth Cardiac Rhythm Management HSD Cardiac Ablation Solutions LSD Cardiovascular Diagnostics LDD Structural Heart & Aortic HSD Cardiac Surgery MSD Coronary LSD Peripheral Vascular Health LSD Onyx Frontier™ DES 1) Aurora EV-ICDTM and Pulse SelectTM are not available in the U.S. Medtronic
View entire presentation